Editas Medicine (NASDAQ: EDIT) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Editas Medicine to related companies based on the strength of its earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Editas Medicine and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine 0 5 4 0 2.44
Editas Medicine Competitors 477 2261 6178 119 2.66

Editas Medicine presently has a consensus price target of $27.00, suggesting a potential upside of 13.11%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.13%. Given Editas Medicine’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine has less favorable growth aspects than its competitors.


This table compares Editas Medicine and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Editas Medicine -2,091.36% -67.75% -38.19%
Editas Medicine Competitors -3,945.41% -117.30% -43.55%

Earnings and Valuation

This table compares Editas Medicine and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Editas Medicine $5.64 million -$114.84 million -7.48
Editas Medicine Competitors $207.79 million -$2.30 million 0.67

Editas Medicine’s competitors have higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

70.5% of Editas Medicine shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 19.4% of Editas Medicine shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Editas Medicine has a beta of 4.84, suggesting that its stock price is 384% more volatile than the S&P 500. Comparatively, Editas Medicine’s competitors have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.

About Editas Medicine

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.